Introduction: In treatment of prosthetic vascular graft infection (PVGI), appropriate antimicrobial treatment is crucial for controlling the septic process and preventing re-infection of the new graft. Glycopeptides are the mainstay of treatment for device-related infections by methicillin-resistant Staphylococcus aureus strains, but with some limitations, especially concerning vancomycin-intermediate and glycopeptide-intermediate S. aureus.
View Article and Find Full Text PDFBackground: There exists considerable debate concerning management of prosthetic vascular graft infection (PVGI), especially in terms of antimicrobial treatment. This report studies factors associated with treatment failure in a cohort of patients with staphylococcal PVGI, along with the impact of rifampin (RIF).
Methods: All data on patients with PVGI between 2006 and 2010 were reviewed.
Background: Mortality associated with aortic graft infection is considerable. The gold standard for surgical treatment remains explantation of the graft. However, prognostic factors associated with early mortality due to this surgical procedure are not well-known.
View Article and Find Full Text PDFPurpose Of Review: This review provides a focus on infections of prosthetic vascular grafts used to treat peripheral arterial diseases.
Recent Findings: The incidence of infections varies between 1 and 6%. Risk factors of infection are not well identified.
Objectives: To report clinical characteristics and prognosis of vascular graft infections in Intensive Care Unit (ICU).
Methods: Thirty seven patients consecutively admitted in ICU for suspected or definite vascular graft infection between January 2006 and June 2009 were included.
Results: Staphylococcus species (n = 18) and enterobacteriae (n = 16) were the most frequent causative organisms.
Ann Clin Microbiol Antimicrob
February 2010
Campylobacter coli is a rare cause of bacteremia. We report here the first case of C.coli spondylodiscitis complicated by an aortic aneurysm.
View Article and Find Full Text PDF